The role of TNF-a in chronic inflammatory conditions , intermediary metabolism , and cardiovascular risk

@inproceedings{Popa2007TheRO,
  title={The role of TNF-a in chronic inflammatory conditions , intermediary metabolism , and cardiovascular risk},
  author={Calin Popa and Mihai G. Netea and Piet L. C. M. van Riel and Jos W. M. van der Meer and Anton F. H. Stalenhoef},
  year={2007}
}
The recent insight that inflammation contributes to the development of atherosclerosis and type 2 diabetes mellitus constitutes a major breakthrough in understanding the mechanisms underlying these conditions. In addition, it opens the way for new therapeutic approaches that might eventually decrease the prevalence of these public health problems. Tumor necrosis factor-a (TNF-a) has been shown to play a key role in these processes and thus might be a potential therapeutic target. Increased… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 172 CITATIONS, ESTIMATED 54% COVERAGE

Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy

  • Clinical and Experimental Medicine
  • 2014
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 21 Highly Influenced Citations

  • Averaged 17 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 129 REFERENCES

Atherosclerosis--an inflammatory disease.

  • The New England journal of medicine
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Beneficial effects of cytokine induced hyperlipidemia.

  • Zeitschrift fur Ernahrungswissenschaft
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1988
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

provement of insulin sensitivity in insulin resistant subjects during prolonged treatment with anti - TNF - a antibody infliximab

F. C. Huvers, C. Popa, M. G. Netea, F. H. J. van den Hoogen, C. J. Tack
  • Eur . J . Clin . Invest .
  • 2007